1
|
Naimi Z, El Bessi M, Skouri M, Bohli M, Amor RB, Hamdoun A, Bouguerra G, Haddad R, Kochbati L. P105 Internal mammary chain irradiation in breast cancer patients: Which patterns of practice between controversial benefit and challenging dosimetry? Breast 2023. [DOI: 10.1016/s0960-9776(23)00222-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/16/2023] Open
|
2
|
Ben Amor R, Bohli M, Naimi Z, Aissaoui D, Mejri N, Yahyaoui J, Hamdoun A, Kochbati L. Hypofractionated radiotherapy after breast-conserving surgery: Clinical and dosimetric factors predictive of acute skin toxicity. Strahlenther Onkol 2023; 199:48-54. [PMID: 35943552 DOI: 10.1007/s00066-022-01985-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Accepted: 07/07/2022] [Indexed: 01/18/2023]
Abstract
PURPOSE The purpose of this study was to evaluate acute skin toxicity in early breast cancer patients treated with hypofractionated radiotherapy (HFRT) after breast-conserving surgery and to identify factors predictive for grade ≥ 2 acute skin toxicity. MATERIALS AND METHODS A monocentric retrospective study was carried out using cases treated between December 2017 and November 2020. We analyzed data from 202 patients with early breast cancer treated with 3D hypofractionated RT (40.05 Gy in 15 fractions) to the whole breast with or without regional lymph nodes, followed by 13.35 Gy in 5 fractions to the tumor bed. Acute skin toxicity was monitored during RT according to CTCAE (common toxicity criteria for adverse events) scale. Univariate and multivariate analyses were performed to assess predictive factors of acute skin toxicity. RESULTS Overall, there was no erythema in 9%, grade 1 erythema in 64.5%, grade 2 in 24%, and grade 3 in 2.5%. No grade 4 erythema was seen. Median delay between RT initiating and maximum skin reaction was 22 days (range 4-44 days). No patient interrupted treatment. In univariate analysis, the rate of acute skin toxicity grade 2---3 (G2-3) was significantly higher for patients with larger tumor size (p = 0.02), body mass index > 27 (p = 0.04), and time between chemotherapy (CT) and RT less than 20 days (p = 0.01). Dosimetric risk factors for acute skin toxicity G2‑3 were breast volume > 800 cc (p = 0.000), boost volume > 18 cc (p = 0.002), V105% > 40 cc (p = 0.03), and Dmax > 56 Gy (p = 0.007). CT, trastuzumab, regional lymph node radiation, and age were not correlated with increased skin toxicity. In multivariate analysis, acute skin toxicity correlated with T stage (p = 0.032), breast volume > 800 cc (p = 0.012), boost volume > 18 cc (p = 0.04), and Dmax > 56 Gy (p = 0.035). CONCLUSION Our results confirm that whole breast with or without lymph nodes hypofractionated RT is safe and well tolerated. The factors strongly associated with a decreased risk of G2‑3 skin toxicity are T1, breast volume < 800 c, boost volume < 18 cc, and Dmax < 56 Gy. Long-term follow-up is needed to evaluate late toxicity.
Collapse
Affiliation(s)
- Raouia Ben Amor
- Faculty of Medicine, University of Tunis El Manar, 1007, Tunis, Tunisia. .,Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080, Ariana, Tunisia.
| | - Meriem Bohli
- Faculty of Medicine, University of Tunis El Manar, 1007, Tunis, Tunisia.,Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080, Ariana, Tunisia
| | - Zeineb Naimi
- Faculty of Medicine, University of Tunis El Manar, 1007, Tunis, Tunisia.,Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080, Ariana, Tunisia
| | - Dorra Aissaoui
- Faculty of Medicine, University of Tunis El Manar, 1007, Tunis, Tunisia.,Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080, Ariana, Tunisia
| | - Nesrine Mejri
- Faculty of Medicine, University of Tunis El Manar, 1007, Tunis, Tunisia.,Department of Medical Oncology, Abderrahmen Mami Hospital, 2080, Ariana, Tunisia
| | - Jamel Yahyaoui
- Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080, Ariana, Tunisia
| | - Awatef Hamdoun
- Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080, Ariana, Tunisia
| | - Lotfi Kochbati
- Faculty of Medicine, University of Tunis El Manar, 1007, Tunis, Tunisia.,Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080, Ariana, Tunisia
| |
Collapse
|
3
|
Naimi Z, Bohli M, Ben Rejeb M, Amor RB, Ghorbel L, Yahyaoui S, Bouzid N, Zarraa S, Chaari N, Hamdoun A, Yahyaoui J, Meftah S, Kochbati L. Enhancing Childhood Cancer Care In African Low-Middle Income Countries: A Tunisian Pilot Experience. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.09.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
Naimi Z, El Bessi M, Bohli M, Ben Amor R, Hamdoun A, Kochbati L. Oesophagus exposure in hypofractionated breast cancer radiotherapy: an organ at risk commonly overlooked? Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01475-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
5
|
Setti Boubaker N, Gurtner A, Trabelsi N, Manni I, Blel A, Saadi A, Chakroun M, Naimi Z, Zaghbib S, Ksontini M, Meddeb K, Rammeh S, Ayed H, Chebil M, Piaggio G, Ouerhani S. An insight into the diagnostic and prognostic value of
HOX A13
’s expression in non‐muscle invasive bladder cancer. J Clin Lab Anal 2022; 36:e24606. [PMID: 35853090 PMCID: PMC9459288 DOI: 10.1002/jcla.24606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 05/23/2022] [Accepted: 06/14/2022] [Indexed: 11/15/2022] Open
Abstract
Background Several studies have interrogated the molecular pathways and their interacting genes underlying bladder cancer (BCa) tumorigenesis, yet, the role of homeobox genes is still poorly understood. Specifically, HOXA13, which plays an important role as a major actor in the urogenital tract's development. Methods Immunohistochemical (IHC) staining was performed to inspect the differential expression of HOXA13 protein in non‐muscle‐invasive bladder cancer (NMIBC) and non‐tumoral tissues. A semiquantitative scoring system was adopted to evaluate the IHC labeling. Correlation to clinical parameters was performed by descriptive statistics. Overall survival was estimated by the Kaplan–Meier method and Cox regression model. The functional HOX A13 protein association networks (PPI) were obtained using String 11.0 database. Results HOX A13 exhibited cytoplasmic and nuclear staining. Its expression levels were lower in high‐grade NMIBC (HG NMIBC) compared to low‐grade ones (LG NMIBC). The expression of HOX A13 was correlated to tumor grade (LG/HG) (p = 0.036) and stage (TA/T1) (p = 0.036). Nevertheless, its expression was not correlated to clinical parameters and was not able to predict the overall survival of patients with HG NMIBC. Finally, PPI analysis revealed that HOX A13 seems to be a part of a molecular network holding mainly PBX1, MEIS, ALDH1A2, HOX A10, and HOX A11. Conclusion The deregulation of HOX A13 is not associated with the prognosis of BCa. It seems to be rather implicated in the early initiation of urothelial tumorigenesis and thus may serve as a diagnostic marker in patients with NMIBC. Further experimentations on larger validation sets are mandatory.
Collapse
Affiliation(s)
- Nouha Setti Boubaker
- Laboratory of Proteins Engineering and Bioactive Molecules (LIP‐MB) INSAT University of Tunis Carthage Tunis Tunisia
- UOSD SAFU Department of Research, Diagnosis and Innovative Technologies IRCCS‐Regina Elena National Cancer Institute Rome Italy
- Urology Department Faculty of Medicine Charles Nicolle Hospital University of Tunis‐El Manar Tunis Tunisia
| | - Aymone Gurtner
- UOSD SAFU Department of Research, Diagnosis and Innovative Technologies IRCCS‐Regina Elena National Cancer Institute Rome Italy
- Institute of Translational Pharmacology (IFT) National Research Council (CNR) Rome Italy
| | - Nesrine Trabelsi
- Laboratory of Proteins Engineering and Bioactive Molecules (LIP‐MB) INSAT University of Tunis Carthage Tunis Tunisia
| | - Isabella Manni
- UOSD SAFU Department of Research, Diagnosis and Innovative Technologies IRCCS‐Regina Elena National Cancer Institute Rome Italy
| | - Ahlem Blel
- Pathology Department Faculty of Medicine Charles Nicolle Hospital University of Tunis El Manar Tunis Tunisia
| | - Ahmed Saadi
- Urology Department Faculty of Medicine Charles Nicolle Hospital University of Tunis‐El Manar Tunis Tunisia
| | - Marouene Chakroun
- Urology Department Faculty of Medicine Charles Nicolle Hospital University of Tunis‐El Manar Tunis Tunisia
| | - Zeineb Naimi
- Medical Oncology Department Faculty of Medicine Salah Azaiez Institute University of Tunis‐El Manar Tunis Tunisia
| | - Selim Zaghbib
- Urology Department Faculty of Medicine Charles Nicolle Hospital University of Tunis‐El Manar Tunis Tunisia
| | - Meriam Ksontini
- Pathology Department Faculty of Medicine Charles Nicolle Hospital University of Tunis El Manar Tunis Tunisia
| | - Khedija Meddeb
- Medical Oncology Department Faculty of Medicine Salah Azaiez Institute University of Tunis‐El Manar Tunis Tunisia
| | - Soumaya Rammeh
- Pathology Department Faculty of Medicine Charles Nicolle Hospital University of Tunis El Manar Tunis Tunisia
| | - Haroun Ayed
- Urology Department Faculty of Medicine Charles Nicolle Hospital University of Tunis‐El Manar Tunis Tunisia
| | - Mohamed Chebil
- Urology Department Faculty of Medicine Charles Nicolle Hospital University of Tunis‐El Manar Tunis Tunisia
| | - Giulia Piaggio
- UOSD SAFU Department of Research, Diagnosis and Innovative Technologies IRCCS‐Regina Elena National Cancer Institute Rome Italy
| | - Slah Ouerhani
- Laboratory of Proteins Engineering and Bioactive Molecules (LIP‐MB) INSAT University of Tunis Carthage Tunis Tunisia
| |
Collapse
|
6
|
Amor RB, Bohli M, Naimi Z, Yahyaoui J, Kochbati L. Concurrent Chemoradiotherapy as an Adjuvant Treatment of Primary Central Nervous System Neuroblastoma. Perm J 2022; 26:166-171. [DOI: 10.7812/tpp/21.147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Raouia Ben Amor
- University of Tunis El Manar, Faculty of Medicine of Tunis, Ariana, Tunisia
- Department of Radiation Oncology, Abderrahmen Mami Hospital, Ariana, Tunisia
| | - Meriem Bohli
- University of Tunis El Manar, Faculty of Medicine of Tunis, Ariana, Tunisia
- Department of Radiation Oncology, Abderrahmen Mami Hospital, Ariana, Tunisia
| | - Zeineb Naimi
- University of Tunis El Manar, Faculty of Medicine of Tunis, Ariana, Tunisia
- Department of Radiation Oncology, Abderrahmen Mami Hospital, Ariana, Tunisia
| | - Jamel Yahyaoui
- Department of Radiation Oncology, Abderrahmen Mami Hospital, Ariana, Tunisia
| | - Lotfi Kochbati
- University of Tunis El Manar, Faculty of Medicine of Tunis, Ariana, Tunisia
| |
Collapse
|
7
|
Naimi Z, El Bessi M, Bohli M, Ben Amor R, Yahyaoui J, Hamdoun A, Kochbati L. PO-1889 Coronary arteries exposure in bilateral breast cancer radiotherapy: More caution is needed! Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03852-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
8
|
Ben Amor R, Bohli M, Naimi Z, Yahiaoui J, Kochbati L. 124P Impact of regional lymph node hypofractionated radiotherapy on acute skin toxicity in patients with node-positive breast cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
9
|
Naimi Z, Bennour E, Neji H, El Bessi M, Ben Amor R, Bohli M, Yahyaoui J, Kochbati L. PO-1891 Impact of internal mammary chain irradiation on heart subvolumes doses in breast cancer radiotherapy. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03854-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
10
|
Hemissi I, Boussetta S, Dallali H, Hellal F, Durand G, Voegele C, Ayed H, Zaghbib S, Naimi Z, Ayadi M, Chebil M, Mckay J, Le Calvez-Kelm F, Ouerhani S. Development of a custom next-generation sequencing panel for the determination of bladder cancer risk in a Tunisian cohort. Mol Biol Rep 2022; 49:1233-1258. [PMID: 34854013 DOI: 10.1007/s11033-021-06951-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Accepted: 11/09/2021] [Indexed: 12/24/2022]
Abstract
BACKGOUND Bladder cancer (BCa) is a heterogeneous disease caused by the interaction between environmental and genetic risk factors. The goal of this case-control study was to evaluate the implication of a selected SNP panel in the risk of BCa development in a Tunisian cohort. We were also interested in studying the interaction between this predictive panel and environmental risk factors. METHODS The case/control cohort was composed with 249 BCa cases and 255 controls. The designed Bladder cancer hereditary panel (BCHP) was composed of 139 selected variants. These variants were genotyped by an amplification-based targeted Next-Generation Sequencing (NGS) on the Ion Torrent Proton sequencer (Life Technologies, Ion Torrent technology). RESULTS We have found that rs162555, rs2228000, rs10936599, rs710521, rs3752645, rs804276, rs4639, rs4881400 and rs288980 were significantly associated with decreased risk of bladder cancer. However the homozygous genotypes for VPS37C (rs7104333, A/A), MPG (rs1013358, C/C) genes or the heterozygous genotype for ARNT gene (rs1889740, rs2228099, rs2256355, rs2864873), GSTA4 (rs17614751) and APOBR/IL27 (rs17855750) were significantly associated with increased risk of bladder cancer development compared to reference group (OR 2.53, 2.34, 1.99, 2.00, 2.00, 1.47, 1.96 and 2.27 respectively). We have also found that non-smokers patients harboring heterozygous genotypes for ARNT/rs2864873 (A > G), ARNT/ rs1889740 (C > T) or GSTA4/rs17614751 (G-A) were respectively at 2.775, 3.069 and 6.608-fold increased risk of Bca development compared to non-smokers controls with wild genotypes. Moreover the ARNT CT (rs1889740), ARNT CG (rs2228099), ARNT TC (rs2864873) and GSS GA genotypes were associated with an increased risk of BCa even in absence of professional risk factors. Finally the decision-tree analysis produced a three major BCa classes. These three classes were essentially characterized by an intensity of tobacco use more than 20 pack years (PY) and the CYP1A2 (rs762551) genotype. CONCLUSIONS The determined association between environmental factors, genetic variations and the risk of Bca development may provide additional information to urologists that may help them for clinical assessment and treatment decisions. Nevertheless, the underlying mechanisms through which these genes or SNPs affect the clinical behavior of BCas require further studies.
Collapse
Affiliation(s)
- Imen Hemissi
- Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), INSAT, National Institute of Applied Sciences and Technology of Tunis, University of Carthage, Tunis, Tunisia
| | - Sami Boussetta
- Laboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences of Tunis, Tunis, Tunisia
| | | | - Faycel Hellal
- National Institute of Applied Sciences and Technology of Tunis, University of Carthage, Tunis, Tunisia
| | - Geoffroy Durand
- Centre International de Recherche sur le Cancer CIRC/International Agency for Research on Cancer IARC, Lyon, France
| | - Catherine Voegele
- Centre International de Recherche sur le Cancer CIRC/International Agency for Research on Cancer IARC, Lyon, France
| | - Haroun Ayed
- Urology Department, Charles Nicolle Hospital, Tunis, Tunisia
| | - Selim Zaghbib
- Urology Department, Charles Nicolle Hospital, Tunis, Tunisia
| | - Zeineb Naimi
- Medical Oncology Department, Saleh Azaiez Institute, Tunis, Tunisia
| | - Mouna Ayadi
- Medical Oncology Department, Saleh Azaiez Institute, Tunis, Tunisia
| | - Mohamed Chebil
- Urology Department, Charles Nicolle Hospital, Tunis, Tunisia
| | - James Mckay
- Centre International de Recherche sur le Cancer CIRC/International Agency for Research on Cancer IARC, Lyon, France
| | - Florence Le Calvez-Kelm
- Centre International de Recherche sur le Cancer CIRC/International Agency for Research on Cancer IARC, Lyon, France
| | - Slah Ouerhani
- Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), INSAT, National Institute of Applied Sciences and Technology of Tunis, University of Carthage, Tunis, Tunisia.
| |
Collapse
|
11
|
Hemissi I, Boussetta S, Dallali H, Hellal F, Durand G, Voegele C, Ayed H, Zaghbib S, Naimi Z, Ayadi M, Chebil M, Mckay J, Le Calvez-Kelm F, Ouerhani S. Correction to: Development of a custom next-generation sequencing panel for the determination of bladder cancer risk in a Tunisian cohort. Mol Biol Rep 2022; 49:1259. [PMID: 34977990 DOI: 10.1007/s11033-021-07052-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Imen Hemissi
- Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), INSAT, National Institute of Applied Sciences and Technology of Tunis, University of Carthage, Tunis, Tunisia
| | - Sami Boussetta
- Laboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences of Tunis, Tunis, Tunisia
| | | | - Faycel Hellal
- National Institute of Applied Sciences and Technology of Tunis, University of Carthage, Tunis, Tunisia
| | - Geoffroy Durand
- Centre International de Recherche sur le Cancer CIRC/International Agency for Research on Cancer IARC, Lyon, France
| | - Catherine Voegele
- Centre International de Recherche sur le Cancer CIRC/International Agency for Research on Cancer IARC, Lyon, France
| | - Haroun Ayed
- Urology Department, Charles Nicolle Hospital, Tunis, Tunisia
| | - Selim Zaghbib
- Urology Department, Charles Nicolle Hospital, Tunis, Tunisia
| | - Zeineb Naimi
- Medical Oncology Department, Saleh Azaiez Institute, Tunis, Tunisia
| | - Mouna Ayadi
- Medical Oncology Department, Saleh Azaiez Institute, Tunis, Tunisia
| | - Mohamed Chebil
- Urology Department, Charles Nicolle Hospital, Tunis, Tunisia
| | - James Mckay
- Centre International de Recherche sur le Cancer CIRC/International Agency for Research on Cancer IARC, Lyon, France
| | - Florence Le Calvez-Kelm
- Centre International de Recherche sur le Cancer CIRC/International Agency for Research on Cancer IARC, Lyon, France
| | - Slah Ouerhani
- Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), INSAT, National Institute of Applied Sciences and Technology of Tunis, University of Carthage, Tunis, Tunisia.
| |
Collapse
|
12
|
Hemissi I, Ayed H, Naimi Z, Meddeb K, Ayadi M, Zouari S, Zaghbib S, Talbi E, Chebil M, Ouerhani S. Polymorphisms in NQO1 and MPO genes and risk for bladder cancer in Tunisian population. Mol Genet Genomic Med 2021; 9:e1819. [PMID: 34549902 PMCID: PMC8606214 DOI: 10.1002/mgg3.1819] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Revised: 09/08/2021] [Accepted: 09/09/2021] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND NAD (P) H: quinone oxidoreductase (1) (NQO1-HGNC: 2874) and myeloperoxidase (MPO-HGNC: 7218) are two enzymes involved in phase II of the xenobiotic metabolism pathway. METHODS In this study, a case-control analysis was conducted to investigate the relationship between genetic variations in the NQO1 (C609T, rs1800566; IVS1-27 C >G, rs689452) and MPO (G463A, rs2333227) genes and the risk for bladder cancer among Tunisian population. RESULTS We have found that the MPO 463GA genotype was associated with a decreased risk of developing bladder cancer (p = 0.049; OR = 0.696; 95% CI 0.484-0.999). In contrast, we have found that the NQO1 609CT genotype could increase the risk of bladder cancer patients (p = 0.0039; OR = 1.454; 95% CI = 1.017-2.078). Moreover, patients with "NQO1 609 CT/IVS1-27 CG" genotype show a 2.180-fold increasing risk for developing bladder cancer in comparison to the control group with wild genotype. This OR is estimated at 5.6-fold in smokers patients with "NQO1 609 CT/IVS1-27 CG" genotype. Lastly, study findings suggest that the NQO1 IVS-27 *CG genotype (rs689452) is associated with a risk of progression to muscle invasive bladder cancer. CONCLUSION Our study suggests that environmental risk factors in association to NQO1 genotypes (NQO1 609 CT/IVS1-27 CG) play an important role in the development of bladder cancer in Tunisian population.
Collapse
Affiliation(s)
- Imen Hemissi
- Laboratory of Protein Engineering and Bio‐active MoleculesNational Institute of Applied Science and Technology ‐ University of CarthageTunisTunisia
| | - Haroun Ayed
- Urology DepartmentCharles Nicolle HospitalTunisTunisia
| | - Zeineb Naimi
- Medical oncology department Salah AzaiezTunisTunisia
| | | | - Mouna Ayadi
- Medical oncology department Salah AzaiezTunisTunisia
| | | | - Selim Zaghbib
- Urology DepartmentCharles Nicolle HospitalTunisTunisia
| | - Emna Talbi
- Biochemistry DepartmentCharles Nicolle HospitalTunisTunisia
| | | | - Slah Ouerhani
- Laboratory of Protein Engineering and Bio‐active MoleculesNational Institute of Applied Science and Technology ‐ University of CarthageTunisTunisia
| |
Collapse
|
13
|
Setti Boubaker N, Gurtner A, Trabelsi N, Manni I, Ayed H, Saadi A, Zaghbib S, Naimi Z, Sahraoui G, Zouari S, Meddeb K, Mrad K, Chebil M, Piaggio G, Ouerhani S. The diagnostic applicability of A-type Lamin in non-muscle invasive bladder cancer. Ann Diagn Pathol 2021; 54:151808. [PMID: 34438192 DOI: 10.1016/j.anndiagpath.2021.151808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Revised: 07/04/2021] [Accepted: 08/10/2021] [Indexed: 10/20/2022]
Abstract
PURPOSE Lamin A is a major component of the nuclear lamina maintaining nuclear integrity, regulation of gene expression, cell proliferation, and apoptosis. Its deregulation in cancer has been recently reported to be associated with its prognosis. However, its clinical significance in non-muscle invasive bladder cancer (NMIBC) remains to be defined. MATERIAL/METHODS Immunohistochemical staining and RT-qPCR were performed to screen the expression patterns of Lamin A/C protein and Lamin A mRNA respectively in 58 high and low grade NMIBC specimens. RESULTS Lamin A/C protein was expressed only in the nucleus and less exhibited in NMIBC tissues compared to non-tumoral ones. On the other side, Lamin A mRNA was up-regulated in NMIBC compared to controls. Nevertheless, both expression patterns (protein and mRNA) were not correlated to clinical prognosis factors and were not able to predict the overall survival of patients with high-grade NMIBC. CONCLUSIONS The deregulation of A-type Lamin is not associated with the prognosis of NMIBC, but it could serve as a diagnostic biomarker distinguishing NMIBC patients from healthy subjects suggesting its involvement as an initiator event of tumorigenesis in our cohort.
Collapse
Affiliation(s)
- Nouha Setti Boubaker
- Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia; UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
| | - Aymone Gurtner
- UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy; Institute of Translational Pharmacology, National Research Council, Rome, Italy.
| | - Nesrine Trabelsi
- Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia.
| | - Isabella Manni
- UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
| | - Haroun Ayed
- Urology Department, Charles Nicolle Hospital, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia.
| | - Ahmed Saadi
- Urology Department, Charles Nicolle Hospital, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia.
| | - Selim Zaghbib
- Urology Department, Charles Nicolle Hospital, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia.
| | - Zeineb Naimi
- Medical Oncology Department, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia.
| | - Ghada Sahraoui
- Pathology Department, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia.
| | - Skander Zouari
- Urology Department, Charles Nicolle Hospital, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia.
| | - Khedija Meddeb
- Medical Oncology Department, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia.
| | - Karima Mrad
- Pathology Department, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia.
| | - Mohamed Chebil
- Urology Department, Charles Nicolle Hospital, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia.
| | - Giulia Piaggio
- UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
| | - Slah Ouerhani
- Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia.
| |
Collapse
|
14
|
abdessatar G, Moujahed R, Ben Rejeb M, Hamdoun A, Yahyaoui J, Naimi Z, Kochbati L. PO-1093 Evaluating cardiac structures exposure in deep inspiration breathhold radiotherapy for breast cancer. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07544-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
15
|
Moujahed R, Ben Rejeb M, Ghorbel S, Hamdoun A, Naimi Z, Bohli M, Kochbati L. PO-1074 Is the mean heart dose the best predictor of cardiac toxicity after Hodgkin Lymphoma irradiation? Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07525-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
16
|
Naimi Z, Neji H, Bennour E, Hamdoun A, Yahyaoui J, Hantous S, Kochbati L. Should we delineate coronary arteries in right-sided breast cancer radiotherapy? Breast 2021. [DOI: 10.1016/s0960-9776(21)00161-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
17
|
Naimi Z, Bennour E, Neji H, Hamdoun A, Yahyaoui J, Hantous S, Kochbati L. Radiation dose distribution in cardiac valves in left-sided breast cancer radiotherapy. Breast 2021. [DOI: 10.1016/s0960-9776(21)00162-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
18
|
Amor R, Benna M, Naimi Z, Bohli M, Kochbati L. Radiation therapy as an adjuvant treatment after breast-conserving surgery in ductal carcinoma In situ of the breast. J Radiat Cancer Res 2021. [DOI: 10.4103/jrcr.jrcr_24_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
19
|
Kochbati L, Vanderpuye V, Moujahed R, Rejeb MB, Naimi Z, Olasinde T. Cancer care and COVID-19: tailoring recommendations for the African radiation oncology context. Ecancermedicalscience 2020; 14:1144. [PMID: 33343703 PMCID: PMC7738267 DOI: 10.3332/ecancer.2020.1144] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2020] [Indexed: 12/24/2022] Open
Abstract
Africa is the second most populous continent after Asia comprising 54 countries. Given the healthcare system deficiencies in Africa, the impact of the COVID-19 pandemic was expected to be disastrous. The first case of COVID-19 on the continent was reported in Egypt on 14 February 2020. By 13 May, cases had been reported in all 54 countries. Several practice guidelines specific to radiation oncology departments have been published, including prioritisation criteria for postponing radiotherapy, continuation of treatment, hypofractionation or even omitting radiotherapy. The oncology community in Africa has suddenly needed to protect both patients and caregivers and to ensure continuity of essential clinical services despite several challenges. Considering equipment unavailability, lack of human resources and poor infrastructure, tailoring COVID-19 pandemic management to the African context seems mandatory and a unified approach to guideline development in this context is encouraged. In this article, we discuss contextual issues coming into play, highlighting steps to be taken by radiotherapy centres in Africa to mitigate fallouts from the current pandemic to ensure the safety of our patients and staff as well as the impact on future care.
Collapse
Affiliation(s)
- Lotfi Kochbati
- Radiotherapy department, Abderrahman Mami Hospital 2090, El Manar University. Tunis, Tunisia
| | - Verna Vanderpuye
- National Center for Radiotherapy and Nuclear Medicine, Korle-Bu Teaching Hospital, Accra, PO Box KB369, Ghana
| | - Rim Moujahed
- Radiotherapy department, Abderrahman Mami Hospital 2090, El Manar University. Tunis, Tunisia
| | - Mouna Ben Rejeb
- Radiotherapy department, Abderrahman Mami Hospital 2090, El Manar University. Tunis, Tunisia
| | - Zeineb Naimi
- Radiotherapy department, Abderrahman Mami Hospital 2090, El Manar University. Tunis, Tunisia
| | - Tajudeen Olasinde
- Ahmadu Bello University / Ahmadu Bello University Teaching Hospital, Shika-Zaria, Nigeria
| |
Collapse
|
20
|
Naimi Z, Mahjoubi K, Adouni O, Abidi R, Driss M, Nasr C. Kaposi's sarcoma of the larynx: an unusual location in an HIV-negative patient (a case report). Pan Afr Med J 2020; 37:206. [PMID: 33505574 PMCID: PMC7813656 DOI: 10.11604/pamj.2020.37.206.26175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Accepted: 10/30/2020] [Indexed: 11/11/2022] Open
Abstract
Head and neck involvement of Kaposi’s sarcoma is rarely encountered, especially for the Mediterranean classic subtype. Here we report a case of non-AIDS related laryngeal Kaposi’s sarcoma in a 77-year-old Tunisian man complaining of 4-month history of hoarseness and dysphagia. The patient underwent exclusive local radiotherapy with a prescription dose of 45 Gy delivered in 1.8 Gy daily fractions. He remained complaint-free for 3 months.
Collapse
Affiliation(s)
- Zeineb Naimi
- University of Tunis El Manar, Faculty of Medicine of Tunis, 1007, Tunis, Tunisia.,Department of Radiation Oncology, Salah Azaiez Institute, 1006, Tunis, Tunisia
| | - Khalil Mahjoubi
- Department of Radiation Oncology, Salah Azaiez Institute, 1006, Tunis, Tunisia
| | - Olfa Adouni
- Department of Pathology, Salah Azaiez Institute, 1006, Tunis, Tunisia
| | - Rim Abidi
- Department of Radiation Oncology, Salah Azaiez Institute, 1006, Tunis, Tunisia
| | - Maha Driss
- Department of Pathology, Salah Azaiez Institute, 1006, Tunis, Tunisia
| | - Chiraz Nasr
- Department of Radiation Oncology, Salah Azaiez Institute, 1006, Tunis, Tunisia
| |
Collapse
|
21
|
Naimi Z, Moujahed R, Ben Rejeb M, Ghorbel S, Yahyaoui J, Hamdoun A, Kochbati L. PO-1881: Dosimetric impact of left anterior descending artery contouring in left-sided breast irradiation. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01899-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
22
|
Zaghbib S, Saadi A, Chakroun M, Oueslati A, Bouzouita A, Derouiche A, Ben Slama M, Mahjoubi K, Naimi Z, Nasr C, Mezlini A, Ayedi M, Meddeb K, Ayed H, Chebil M. Enquête nationale sur la pratique de la surveillance active pour cancer de la prostate en Tunisie. Prog Urol 2020. [DOI: 10.1016/j.purol.2020.07.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
23
|
Setti Boubaker N, Gurtner A, Trabelsi N, Manni I, Ayed H, Saadi A, Naimi Z, Ksontini M, Ayadi M, Blel A, Rammeh S, Chebil M, Piaggio G, Ouerhani S. Uncovering the expression patterns and the clinical significance of miR-182, miR-205, miR-27a and miR-369 in patients with urinary bladder cancer. Mol Biol Rep 2020; 47:8819-8830. [PMID: 33128684 DOI: 10.1007/s11033-020-05932-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2020] [Accepted: 10/17/2020] [Indexed: 12/30/2022]
Abstract
BACKGROUND Given the high recurrence and progression rates and the absence of reliable markers for early detection and prognosis prediction of patients with urothelial bladder cancer (BCa), the exploration of new biomarkers with high specificity is imperative. Mainly, microRNAs (miRNAs), which are involved in the initiation and the progression of BCa. Herein, the expression patterns of miR-182, miR-205, miR-27a and miR-369 were evaluated in patients with urothelial BCa. METHODS AND RESULTS The expression levels of the miRNAs were investigated in 90 FFPE tissue samples (23 LG NMIBC, 44 HG NMIBC, 23 MIBC) and 10 non tumoral bladder tissues using TaqMan based RT-qPCR. Data analysis was performed using 2-ΔΔCT method. Correlation to clinical characteristics of the patients was performed using descriptive statistics and the receiver operating characteristic (ROC) curve was performed to evaluate the diagnostic value of all miRNAs. MiR-27a, miR-205 and miR-369 were down-regulated whereas miR-182 was up-regulated in patients compared to controls (p < 0.001). MiR-205 and miR-182 positively segregate between NMIBC and MIBC (p = 0.002 and p = 0.000 respectively) whereas the distribution of miR-27a's expression among these tumor groups was almost significant (p = 0.05) and that of miR-369's expression was irrelevant (p = 0.618). Interestingly, miR-182 was discriminative between LG NMIBC and HG NMIBC (p < 0.001) and Ta/T1 tumors (p = 0.000). Furthermore, high levels of miR-182 were potentially predictive of progression in NMIBC patients (p = 0.01). CONCLUSION Collectively, a selection of miRNAs was found to be aberrantly expressed in BCa suggesting a potential diagnostic value in BCa. In addition, the clinical value of miR-182 and miR-205 as potential prognosis biomarkers was highlighted. Indeed, our data provide additional insights into cancer biology. Further functional or target studies are mandatory to strengthen these findings.
Collapse
Affiliation(s)
- Nouha Setti Boubaker
- Laboratory of proteins engineering and bioactive molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia.
- UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
| | - Aymone Gurtner
- UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy
- Institute of Translational Pharmacology, National Research Council, Rome, Italy
| | - Nesrine Trabelsi
- Laboratory of proteins engineering and bioactive molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia
| | - Isabella Manni
- UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy
| | - Haroun Ayed
- Laboratory of proteins engineering and bioactive molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia
- Urology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia
| | - Ahmed Saadi
- Laboratory of proteins engineering and bioactive molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia
- Urology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia
| | - Zeineb Naimi
- Medical Oncology Department, Salah Azaiez Institute, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia
| | - Meriem Ksontini
- Pathology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia
| | - Mouna Ayadi
- Medical Oncology Department, Salah Azaiez Institute, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia
| | - Ahlem Blel
- Pathology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia
| | - Soumaya Rammeh
- Pathology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia
| | - Mohamed Chebil
- Urology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia
| | - Giulia Piaggio
- UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
| | - Slah Ouerhani
- Laboratory of proteins engineering and bioactive molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia
| |
Collapse
|
24
|
Abbes I, Abdelhak S, Abdelhedi C, Abid K, Abidi R, Acacha E, Achour S, Achour A, Adouni O, Afrit M, Ahlem A, Akik I, Akremi M, Aloui R, Aloulou S, Ammar N, Arem S, Athimni S, Attia L, Attia M, Ayadi M, Ayadi A, Ayadi K, Ayadi H, Ayadi L, Ayadi I, Ayari J, Azzouz H, Bacha D, Bahloul R, Bahri I, Bahri M, Bakir D, Balti M, Bargaoui H, Batti R, Bayar R, Bdioui Thabet A, Beji M, Bel Hadj Hassen S, Bel Haj Ali A, Belaid I, Belaid A, Beldjiilali Y, Belkacem O, Bellamlih O, Ben Abdallah W, Ben Abdallah M, Ben Abdellah H, Ben Abderrahmen S, Ben Ahmed S, Ben Ahmed K, Ben Ayache M, Ben Ayoub W, Ben Azaiz M, Ben Azouz M, Ben Daly A, Ben Dhia S, Ben Dhiab M, Ben Dhiab T, Ben Fatma L, Ben Ghachem D, Ben Hammadi S, Ben Hassen M, Ben Hassena R, Ben Hassouna J, Ben Kridis W, Ben Leila F, Ben Mahfoudh KH, Ben Mustapha N, Ben Nasr S, Ben Othman F, Ben Rejeb M, Ben Rekaya M, Ben Rhouma S, Ben Safta Z, Ben Safta I, Ben Said A, Ben Salah M, Ben Salah H, Ben Slama S, Ben Temime R, Ben Youssef Y, Ben Zid K, Benabdella H, Benasr S, Bengueddach A, Benna M, Benna F, Bergaoui H, Berrazaga Y, Besbes M, Bhiri H, Bibi M, Blel A, Bohli M, Bouali S, Bouaouina N, Bouassida K, Bouaziz H, Boubaker J, Boudaouara T, Boudaouara Z, Boudaouara O, Boughanmi F, Boughattas W, Boughizane S, Bouguila H, Bouhani M, Bouhlel B, Boujelbane N, Boujemaa M, Boulma R, Bouraoui S, Bouriga R, Bourmech M, Bousrih C, Boussen H, Boussen N, Bouzaien F, Bouzayene F, Brahem I, Briki R, Chaabene K, Chaabouni M, Chaari H, Chabchoub I, Chachia S, Chaker K, Chamlali M, Charfi L, Charfi M, Charfi S, Charradi H, Cheffai I, Chelly B, Chelly I, Chenguel A, Cherif A, Cherif O, Chiboub A, Chouchene A, Chraiet N, Daghfous A, Daldoul A, Daoud N, Daoud J, Daoud R, Daoud E, Debaibi M, Dhaouadi S, Dhief R, Dhouib F, Dimassi S, Djebbi A, Doghri R, Doghri Y, Doudech B, Dridi M, El Amine O, El Benna H, El Khal MC, Eladeb M, Elloumi M, Elmeddeb K, Enaceur F, Ennouri S, Essoussi M, Ezzairi F, Ezzine A, Faleh R, Fallah S, Faouzi N, Fathallah K, Fehri R, Feki J, Fekih M, Fendri S, Fessi Z, Fourati N, Fourati M, Frikha I, Frikha M, Gabsi A, Gadria S, Gamoudi A, Gargoura A, Gargouri W, Ghariani N, Ghazouani E, Ghorbal A, Ghorbel L, Ghorbel S, Ghozzi A, Glili A, Gmadh K, Goucha A, Gouiaa N, Gritli S, Guazzah K, Guebsi A, Guermazi Z, Guermazi F, Gueryani N, Guezguez M, Hacheni F, Hachicha M, Haddad A, Haddaoui A, Hadoussa M, Haj Mansour M, Hajjaji A, Hajji A, Hamdi A, Hamdi Y, Hammemi R, Haouet S, Hdiji A, Hechiche M, Hedfi M, Helali AJ, Henchiri H, Heni S, Hentati A, Herbegue K, Hidar S, Hlaf M, Hmida W, Hmida I, Hmida L, Hmila Ben Salem I, Hochlef M, Hsairi M, Jaffel H, Jaidane M, Jarraya H, Jebsi M, Jedidi M, Jlassi A, Jlassi H, Jmal H, Jmour O, Jouini M, Kabtni W, Kacem M, Kacem S, Kacem I, Kaid M, Kairi H, Kallel M, Kallel R, Kallel F, Kammoun H, Kamoun S, Kanoun Belajouza S, Karray W, Karrit S, Karrou M, Kchir N, Kdous S, Kehili H, Keskes H, Khairi H, Khalfallah MT, Khalifa MB, Khanfir A, Khanfir F, Khechine W, Khemiri S, Khiari H, Khlif A, Khouni H, Khrouf S, Kochbati L, Korbi I, Korbi A, Krir MW, Ksaier I, Ksantini R, Ksantini M, Ksantini F, Ktari K, Laabidi S, Laamouri B, Labidi A, Lahmar A, Lahouar R, Lamine O, Letaief F, Limaiem F, Limayem I, Limem S, Limem F, Loghmari A, M'ghirbi F, Maamouri F, Magherbi H, Mahjoub N, Mahjoub M, Mahjoubi K, Majdoub S, Makhlouf T, Makni A, Makni S, Mallat N, Manai MH, Mansouri H, Maoua M, Marghli I, Masmoudi T, Mathlouthi N, Meddeb K, Medini B, Mejri N, Merdessi A, Mesali C, Mezlini E, Mezlini A, Mezni E, Mghirbi F, Mhiri N, Mighri N, Mlika M, Mnejja W, Mnif H, Mokni M, Mokrani A, Mosbah F, Moujahed R, Mousli A, Moussa A, Mrad Dali K, Mrizak N, Msakni I, Mzabi S, Mzali R, Mzoughi Z, Naimi Z, Najjar S, Nakkouri R, Nasr C, Nasrallah D, Nasri M, Njim L, Noubigh GEF, Nouira Y, Nouri O, Omrani S, Osmane W, Ouanes Y, Ouanna N, Oubich F, Oumelreit Belamlih G, Rachdi H, Rafraf F, Rahal K, Raies H, Rammeh S, Rebaii N, Rekik W, Rekik H, Rhim MS, Rhim S, Rihab D, Rjiba R, Rziga T, Saad H, Saad A, Saadi M, Said N, Salah R, Sallemi N, Sassi A, Sassi K, Sassi Mahfoudh A, Sbika W, Sellami A, Serghini M, Sghaier S, Sh Zidi Y, Siala W, Slimane M, Slimani O, Soltani S, Souguir MK, Sridi A, Tabet Zatla A, Tajina D, Talbi G, Tbessi S, Tebra Mrad S, Temessek H, Tlili G, Toumi N, Toumi O, Toumia N, Tounsi H, Trigui E, Triki M, Triki A, Turki M, Werda I, Yahyaoui S, Yahyaoui Y, Yaich A, Yamouni M, Yazid D, Yousfi A, Zaghouani H, Zaied S, Zairi F, Zaraa S, Zehani A, Zenzri Y, Zidi A, Znaidi N, Zouari K, Zouari S, Zoukar O, Zribi A. Summaries of the papers of the 4th National Congress of the Tunisian Society of Medical Oncology attached to the 4th Maghreb Congress of Oncology. Tunis Med 2017; 95:859-964. [PMID: 29873056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
|